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Objectives: Macroprolactinaemia is a known benign
cause of hyperprolactinaemia (hyperPRL). Differenti-
ating macroprolactinaemia and hyperPRL is important,
as macroprolactinaemia does not require treatment. This
study was conducted to determine the prevalence of
macroprolactinaemia among hyperPRL patients through
the use of polyethylene glycol 8000.
Methods: From 2011 to 2013, a cross-sectional study was
conducted on patients diagnosed with hyperPRL in
Hospital Universiti Sains Malaysia (HUSM). Sera from
these patients were measured for PRL using cobas e411
(Roche Diagnostics, Indianapolis, USA) (sandwich
principle) and the same sera were treated with poly-
ethylene glycol (PEG) 8000 to differentiate true
hyperPRL from macroprolactinaemia. PRL recovery of
less than 40% was used as an indicator of the presence of
macroprolactin.
Results: A total of 133 hyperPRL patients, 120 (90%)
women and 13 (9.8%) men, aged 18e68 years, with mean
(standard deviation) age 34.37 (11.75) years comprised
this study cohort. Nine female patients were found to
have macroprolactinaemia with an estimated prevalence
of 6.8% (95% CI: 2.4%, 11.1%).
Conclusions: The prevalence of macroprolactinaemia
detected using PEG 8000 among patients diagnosed as
hyperPRL was low. Screening for macroprolactin usingy. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2016.08.001
N.A.A. Che Soh et al. 465PEG 8000 indicated that the majority of patients who
presented with hyperPRL in HUSM were true hyperPRL.
Keywords: Hyperprolactinemia; Macroprolactin; Macro-
prolactinemia; PEG 8000
 2016 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Prolactin (PRL) is a polypeptide hormone, consisting of
199 amino acids that is synthesized in and secreted by lac-
totroph, which are specialized cells of the anterior pituitary
gland. PRL is secreted episodically by the anterior pituitary
and is primarily under tonic inhibitory control of the
hypothalamus.1
PRL is synthesized as a prehormone with a molecular
weight of 26 kDa.2 When the prehormone is proteolytically
cleaved, the resulting mature polypeptide has a molecular
mass of 23 kDa, and this monomeric form accounts for
the majority (85%) of total PRL in the serum of normal
subjects.1 In addition to monomeric PRL, other
molecular mass variants of PRL can be demonstrated in
serum. Big PRL has a molecular mass in the 50 kDa
range and is thought to be a covalently bound dimer of
PRL, accounting for approximately 10e15%. Big big
PRL or macroprolactin, which has a molecular mass of
more than 150 kDa, usually contributes a small, though
variable amount to circulating levels.2 Moreover, post-
translational modification of pituitary PRL generates a
variety of additional species, including glycosylated and
phosphorylated variants, together with 14, 16 and 22 kDa
proteolysed forms,1 and has three intramolecular
disulphide bonds.3
Physiological levels of PRL are higher during pregnancy
and lactation than otherwise, and mean serum levels are
higher in women than in men.2 HyperPRL is a condition of
excess monomeric PRL. The clinical syndromes of
hyperPRL are galactorrhoea, oligomenorrhoea,
amenorrhoea, and infertility in women; and reduced libido,
oligospermia, impotence and galactorrhoea in men.4
HyperPRL has an estimated prevalence of 15% in women
with secondary amenorrhoea, a condition that affects at
least 3% of women of reproductive age.5
In general, macroprolactin is a non-bioactive prolactin
isoform, usually composed of a PRL monomer and an IgG
molecule that has a prolonged clearance rate similar to that
of immunoglobulins. This isoform is clinically non-reactive
but interferes with immunological assays used for the
detection of PRL.6 When the serum of a patient with
hyperPRL contains mostly big big PRL, the condition is
termed macroprolactinaemia. Because certain laboratories
fail to screen hyperprolactinaemic sera for macroprolactin,
this may lead to misdiagnosis and unnecessary medical and
surgical intervention7 or delayed diagnosis and
inappropriate treatment.8,9Screening hyperprolactinaemic sera for the presence of
misleading concentrations of macroprolactin is readily per-
formed in biochemistry laboratories, although the proced-
ures are not automated. The most widely employed method
is to treat the hyperprolactinaemic serum with PEG, which
precipitates out high-molecular weight constituents
including immunoglobulins. Re-assay of the serum for PRL
will then identify those sera, which yield values within the
relevant normal range indicative of macroprolactinaemia,
and not true hyperPRL.10Materials and Methods
A cross-sectional study was conducted in 2013 involving
patients aged 18 years old, in Kelantan, who were investi-
gated for hyperPRL, and who attended Endocrine Clinic
HUSM from 2010 to 2013. PRL levels which were above the
reference range for our hospital for age and sex (female-non
pregnant: 0.21e1.0 nmol/L, male: 0.17e0.65 nmol/L) were
included in this study. These interval values were used, as
hyperPRL was defined as a level of PRL above the upper
limit of normal PRL level, in a single measurement, as
described by Melmed et al. 2011.11
The number of serum samples required to determine the
prevalence of patients with macroprolactinaemia was
calculated using the one-sample proportion formula, and
with the Type I error and study precision at 5%, the number
of serum samples required was from 196 subjects.
Inclusion criteria in this study were: patient with PRL
level of >0.65 nmol/L for male patients and >1.0 nmol/L for
female patients. We excluded patients with inadequate or
missing serum samples and patients with more than 30%
missing data. After applying inclusion and exclusion criteria,
only 133 serum samples were available. Since the calculated
sample size was larger than the number of serum samples
available, no sampling method was applied and all serum
samples were included in the study. These serum samples
were stored at 20 C until further analysis.
Data on presenting symptoms and medical history were
extracted from hospital medical records. This study was
approved by the Human Research Ethics Committee of
USM (HREC) USMKK/PPP/JEPeM [263.4(1.4)]. All as-
pects of this study comply with the Declaration of Helsinki.
A volume of 250 mL of the patient’s serum was treated
with 250 mL of PEG 8000 (25% w/v) solution. The mix-
tures were mixed for approximately ten seconds in a
rotating shaker and centrifuged between 1500 and 10,000 g
for five minutes. The supernatant was measured for PRL
and results were expressed as percentage of PRL recovery.
The recovery of PRL post-PEG was calculated using the
following formula: % Recovery post PEG
precipitation ¼ (PRL value post PEG precipitation/PRL
value in pre PEG)  2  100%.
Data were entered and analysed using SPSS version 21.
Exploratory data analysis was conducted to determine the
distribution of numerical data and frequency of categorical
data. Numerical data with normal distribution are presented
as the mean and standard deviation (SD), whereas for
skewed data, data are presented as median and interquartile
range (IQR). The prevalence of patients with macro-
prolactinaemia and 95% CI was calculated.
Table 1: Descriptive statistics for overall subjects (n[ 133).
Variables Mean (SD) n (%)
Age 34.37 (11.75)
Sex
Female 120 (90.2)
Male 13 (9.8)
Race
Malay 123 (92.5)
Chinese 5 (3.8)
Indian 1 (0.8)
Others 4 (3.0)
Pre PEG (mg/mL) 1.50 (1.30)a
Post PEG (mg/mL) 11.91 (10.40)a
PEG Recovery (%) 66.21 (18.14)
Oligomenorrhoea
No 105 (78.9)
Yes 28 (21.1)
Amenorrhoea
No 109 (82.0)
Yes 24 (18.0)
Galactorrhoea
No 105 (78.9)
Yes 28 (21.1)
Infertility
No 74 (55.6)
Yes 59 (44.4)
Headache
No 118 (88.7)
Yes 15 (11.3)
Eye symptoms
No 117 (88.0)
Yes 16 (12.0)
a Median (IQR).
Table 2: Demographic data and clinical history for patients
with PEG recovery < 40%.
Patient
no
Age
(years)
Gender Race Clinical history
1 44 Female Malay Complex partial seizure
on antiepileptic
2 60 Female Malay Eye symptom
(reduced vision)
3 19 Female Malay Polycystic ovary
syndrome (PCOS)
4 38 Female Chinese Primary infertility
5 37 Female Malay Secondary infertility
6 34 Female Malay Primary infertility
7 26 Female Malay Infertility, oophorectomy
secondary to endometriosis
8 31 Female Malay Secondary amenorrhoea
9 18 Female Malay Investigation for
temporal lobe epilepsy
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In this study, 133 samples were analysed to screen for
macroprolactinaemia. The majority of patients were Malay
females (Table 1).
Nine samples [prevalence¼6.8%(95%CI¼2.4%,11.1%)],
had post-PEG recovery levels of <40%, and there were 20
samples (15.0%) with recovery between 40% and 60%. The
remaining 104 (78.2%) samples had recovery >60%. All nine
patients with recovery <40% were female and presented with:
infertility problems (four patients), secondary amenorrhoea
(one patient), investigation of temporal lobe epilepsy (one pa-
tient), complex partial seizure on antiepileptic (one patient),
polycystic ovary syndrome (one patient), and eye symptoms-
reduced vision (one patient). None of these patients had un-
dergoneanyimagingstudy, suchasCTscanorMRIofthebrain
or were being treated with dopamine agonist therapy. De-
mographic data and clinical history for patients with PEG re-
covery<40% are shown in Table 2.
Discussion
Macroprolactinaemia is a benign variant of HyperPRL.12
Nevertheless, identification of macroprolactin in sera is
important, as it has a clinical impact leading to diagnostic
confusion. Failure to differentiate between true HyperPRL
and macroprolactinaemia may lead to unnecessary
investigation, inappropriate treatment and a delayed correctdiagnosis.10 Symptoms of hyperprolactinaemic syndrome are
common and non-specific,13 limiting the diagnostic value of
clinical symptoms to differentiate between true hyperPRL
and macroprolactinaemia.
In true hyperPRL, inhibition of hypothalamic
gonadotrophin-releasing hormone by PRL leads to hypo-
gonadotropic hypogonadism, which then causes oligome-
norrhoea or amenorrhoea.14 These conditions are
characterized by low levels of oestradiol and low or
inappropriate concentrations of FSH and LH, reflecting
the hypothalamic origin of the disturbance.
Symptoms of hyperprolactinaemic syndrome are also
commonly found in patients with macroprolactinaemia, and
the exact mechanism of the clinical symptoms in these patients
is not thoroughly understood. A study that investigated the
relationship between clinical symptoms and macro-
prolactinaemia suggested that macroprolactin may be the
reason the patientwithmacroprolactinaemia has symptoms.15
Several studies found that the association between the
relatively common symptoms of galactorrhoea and oligo-
menorrhoea with the biochemical finding of macro-
prolactinaemia is coincidental.7,16 In macroprolactinaemia,
macroprolactin is confined to the vasculature and has
limited bioactivity in vivo. This condition might explain
why macroprolactinaemia patients are asymptomatic.9 This
finding was supported by Suliman et al. who found that
compared with true hyperprolactinaemic subjects, plasma
levels of oestradiol and LH were significantly higher in
individuals with macroprolactinaemia, consistent with the
limited bioactivity of macroprolactin.8
In this study, four out of the nine macroprolactinaemia
patients presented with infertility problems, either primary
or secondary, which accounted for 6.8% of the infertility
patients. Some studies have showed that the prevalence of
macroprolactinaemia among infertility patients is about ten
to 12%.17,18 Due to difficulties in differentiating true
hyperprolactinaemia and macroprolactinaemia, screening is
highly recommended because patients with
macroprolactinaemia should be investigated for causes of
infertility, as the management is different.
In this study, 90% of patients were female, and only 9.8%
were male. Among these patients, nine were found to have
N.A.A. Che Soh et al. 467macroprolactinaemia and all were female. None of the male
patients was found to have macroprolactinaemia. No sig-
nificant association was found between gender and macro-
prolactinaemia in this study. This finding agrees with
previous studies that also reported no significant association
between gender and macroprolactinaemia.19
Previous studies have also reported a higher prevalence of
macroprolactinaemia among females.16,20,21 This could be
due to, compared to men being investigated for sexual
dysfunction, a higher number of female patients being
investigated for infertility and menstrual disturbances.22,23
The prevalence of macroprolactinaemia among
hyperPRL patients in this study is 6.8%, which is almost
similar to previously reported prevalences.24,25 However,
compared to the current study,26,27 other studies have
reported a higher prevalence. The prevalence of
macroprolactinaemia in hyperprolactinaemia, in other
populations, found by other researchers, ranged from 15%
to 46%. The difference in the prevalence of our study may
possibly be due to patient selection, prolactin level and also
the analyser that was used.
For the patients with recovery between 40% and 60%,
further confirmation by GFC needs to be completed to
confirm the presence of either monomeric prolactin or
macroprolactin. However, GFC was not performed and is
beyond the scope of this study.
In our lab, PRL measurement is performed by Elecsys II,
which has been shown to have relatively low reactivity to-
ward macroprolactin, similar to Advia Centaur and Access/
Dxl (Beckman).7,28 This may be a reason why our prevalence
of macroprolactinaemia is very similar to Jamaluddin et al.
and Jassam et al. who both used Advia Centaur.24,25
In this study, PEG 8000 was used in a similar method to
other previously conducted studies.8,29,30 However, other
studies used PEG 6000 instead of PEG 800031e33.
Although it has been reported that there was no significant
difference in PRL levels between post-PEG 6000 and post-
PEG 8000, a significant constant bias has been observed in
these two tests. Laboratories that use PEG 8000 should
therefore exercise caution, when interpreting post-PEG PRL
levels using reference values established with PEG 6000.34
The cut-off of <40% was used to indicate the presence of
macroprolactin,31,35 as a PEG recovery of <40% has been
shown to be 100% sensitive for detecting macroprolactin.
Most studies identify a grey area with recovery between
40% and 60%; at this level it has been shown that the
sample may contain monomer PRL together with
macroprolactin. Therefore, GFC is recommended to detect
the presence of macroprolactin, and this finding is
supported by previous research.24
The gold standard for the determination of macro-
prolactin is gel filtration chromatography (GFC), which al-
lows quantitation of all forms of PRL and estimates its
molecular mass. This method, however, is time consuming,
expensive and generally not suitable for the routine clinical
laboratory.5 PEG is therefore considered the most
recommended method for the detection of macroprolactin.30
There were several limitations in our study. Compared to
the sample size calculations, the number of patients in our
study was relatively small. It would be desirable to have a
multicentre study, in order to see the true prevalence of
macroprolactinaemia in our population. A larger number ofmale patients and infertility patients also may be needed to
look for macroprolactin in these groups of patients.
As this is a cross-sectional study, the records cannot be
reviewed for further evaluation of hormonal status and thus
cannot be assessed. This study used a leftover sample;
therefore, there was only a small amount of sera, and there
was not enough for further analysis of other hormones and
to study the association of hormonal changes in these pa-
tients. As in the records review, there were few missing re-
cords and data, which enables further detailed study of the
patients. Further follow-up in these patients would be
beneficial to study the nature of the symptoms: do symptoms
persist or resolve, with or without treatment?
Conclusions
Screening for macroprolactin is necessary and has been
highly recommended by several studies, but the decision for
screening must be accordingly made by the attending
physician. At present, this screening should not be routinely
performed, due to laboratory costs. However, if cost is not a
problem, screening is most beneficial to both patients and
attending physicians. As the main clinical approach in
hyperprolactinaemic patients is to determine the cause of
hyperprolactinaemia, as the management differs according
to primary cause, it is also important to identify which pa-
tients require further evaluation and treatment. Therefore,
detecting macroprolactinaemia is very important. When the
presence of macroprolactin is at a normal level of monomeric
PRL, patients do not need further imaging study and do not
require a dopamine agonist. Preferably, laboratories should
establish the reference intervals, providing a measurement of
bioactive PRL, which provides the most useful information
for clinicians.
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